Foxp3 is a key downstream regulator of p53-mediated cellular senescence.
Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS.
Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors.
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505).
Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer.
Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations.
HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.
Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study.
The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small-cell lung cancer.
Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).
Corrigendum to 'L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells': [Free Radic. Biol. Med. 95 (2016) 200-208].
Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed.
Second-generation anaplastic lymphoma kinase inhibitors: revolutionary or evolutionary?
Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned.
A Case of Guillain-Barre Syndrome and Myositis Associated with Preceding Hepatitis E Virus Infection
Screening of EML4-ALK fusion variant subtypes for predicting response to the ALK inhibitors in patients with a non-small cell lung cancer
RandomizEd phase II trial of Sunitinib four-week on and two-week off vs.Two-week On and one-week off in metastatic clear cell type REnal cell carcinoma: RESTORE trial (NCT00570882)
Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI) is Active in Patients with Metastatic Renal Cell Carcinoma (mRCC) with Poor Risk Features
Comparative Efficacy of Sunitinib versus Sorafenib as First-line Treatment for Patients with Metastatic Renal Cell Carcinoma
Gamma Knife Surgery (GKS) Alone versus GKS Followed by Whole Brain Radiotherapy (WBRT) as the Initial Treatment of Brain Metastasis
Clinical characteristics, survival and prognostic factors of advanced renal cell carcinoma with predominant sarcomatoid histology
A Phase II study of Erlotinib for Patients with Advanced/Metastatic Non-small Cell Lung Cancer Who Had Failed Gefitinib
Phase II study of erlotinib as a first-line therapy for non-small-cell lung cancer patients according to their clinical predictors.
Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never smokers with adenocarcinoma of the lung and asymptomatic synchronous brain metastasis.
Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer
Frontline cytotoxic chemotherapy (CTx) for newly diagnosed non-small cell lung cancer (NSCLC) patients presenting with brain metastasis compared to whole brain radiotherapy (WBRT)